Readministration of nivolumab for patients with advanced gastric cancer: a case series

Background: Nivolumab (NIVO), an immune checkpoint inhibitor (ICI) combined with chemotherapy, represents the standard of care for patients with human epidermal growth factor receptor 2-negative advanced gastric cancer (AGC). Although ICI readministration either as a rechallenge following disease pr...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	H. Kodama, Y. Narita, K. Honda, T. Masuishi, H. Taniguchi, S. Kadowaki, M. Ando, M. Tajika, T. Yamaguchi, H. Nishikawa, K. Muro
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2026-03-01
Cyfres:	ESMO Gastrointestinal Oncology
Pynciau:	gastric cancer nivolumab readministration rechallenge reintroduction
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2949819826000075
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!